Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Eldon Leutzinger"'
Autor:
Joseph J Progar, Eldon Leutzinger, Charles R. Brownell, Joan C. May, Ajaz S. Hussain, Patrick J. Faustino, Yongsheng Yang, Mansoor A. Khan, Sally A. Loewke, Nakissa Sadrieh, Vincent J. Mecozzi, Eric P. Duffy, David A. Place, Florence Houn, Christopher D. Ellison, Robbe C. Lyon
Publikováno v:
Journal of Pharmaceutical and Biomedical Analysis. 47:114-125
Ferric hexacyanoferrate (Fe4III[FeII(CN)6]3), also known as insoluble Prussian blue (PB) is the active pharmaceutical ingredient (API) of the drug product, Radiogardase. Radiogardase is the first FDA approved medical countermeasure for the treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aadb9423e388b8ee6f143b29159b280
https://doi.org/10.1016/j.jpba.2007.11.049
https://doi.org/10.1016/j.jpba.2007.11.049
Autor:
Eric P. Duffy, David A. Place, Charles R. Brownell, Nakissa Sadrieh, Alfred V. Del Grosso, Joan May, Yongsheng Yang, Robbie Lyon, Ruyi He, Patrick J. Faustino, Eldon Leutzinger, Florence Houn
Publikováno v:
Clinical Toxicology. 45:776-781
Background. Prussian Blue (PB), ferric hexacyanoferrate is indicated for (oral) treatment of internal contamination with radioisotopes of cesium or thallium. Cyanide is 35–40% of PB's molecular composition, thus cyanide may be released during trans
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::541c46cb4a76fd728b5a17fbc67ae0b4
https://doi.org/10.1080/15563650601181562
https://doi.org/10.1080/15563650601181562
Autor:
Qi Liu, Hui Zhang, Pengfei Song, V. Ellen Maher, Martin T. Haber, Eldon Leutzinger, Shenghui Tang, Robert Justice, Elleni Alebachew, William F. Pierce, Paul G. Kluetz, Amna Ibrahim, Todd Palmby, Richard Pazdur, Rajeshwari Sridhara, Ali Al-Hakim, Wei Chen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 20(1)
On May 15, 2013, the U.S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Ra-223; Xofigo injection; Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0125917b5b439714d6e18a6cba4259b8
https://pubmed.ncbi.nlm.nih.gov/24190979
https://pubmed.ncbi.nlm.nih.gov/24190979
Autor:
Yongsheng Yang, David A. Place, Joseph J Progar, Joan C. May, Mansoor A. Khan, Robbe C. Lyon, Patrick J. Faustino, Eldon Leutzinger, Charles R. Brownell, Nakissa Sadrieh, Lawrence X. Yu, Eric P. Duffy
Publikováno v:
International journal of pharmaceutics. 353(1-2)
Ferric hexacyanoferrate, (Fe(4)(III)[Fe(II)(CN)(6)](3)), also known as insoluble Prussian blue (PB), is the active pharmaceutical ingredient (API) of Radiogardase which is the first approved drug product (DP) for treatment of thallium and radiocesium
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70682f9255c7ff6ef8b5fe5326e6d127
https://pubmed.ncbi.nlm.nih.gov/18226478
https://pubmed.ncbi.nlm.nih.gov/18226478